Exome Asset Management
NEW YORK, NYfiles as Exome Asset Management LLC
$162m in 52 US stocks at the end of 30 June 2026. The top 10 are 44.6% of the money. It changed about 27.7% of the portfolio this quarter.
Value
$162m
Stocks
52
Top 10 share
44.6%
Turnover
27.7%
What changed this quarter
New
Bought for the first time this quarter.
- TG TherapeuticsTGTX5.6% of the fund
- Abivax SAABVX3.9% of the fund
- uniQureQURE2.3% of the fund
- AstrazenecaAZN1.4% of the fund
- Viking TherapeuticsVKTX1.2% of the fund
- Ocular TherapeutixOCUL1.1% of the fund
- EquilliumEQ1.1% of the fund
- Ascendis Pharma A/SASND1.1% of the fund
- Nektar TherapeuticsNKTR1.0% of the fund
- ClearPoint NeuroCLPT0.9% of the fund
- Caris Life SciencesCAI0.9% of the fund
- GeronGERN0.5% of the fund
- Bright Minds BiosciencesDRUG0.4% of the fund
- Compass TherapeuticsCMPX0.4% of the fund
- Replimune GroupREPL0.3% of the fund
Added
Bought more of a stock they already held.
- Maze TherapeuticsMAZE2.1% of the fund+30%
Cut
Sold some of their stake.
- Guardant HealthGH6.2% of the fund-18%
- Praxis Precision MedicinesPRAX5.6% of the fund-40%
- Cogent BiosciencesCOGT5.0% of the fund-24%
- Ionis PharmaceuticalsIONS4.3% of the fund-20%
- Eli LillyLLY4.1% of the fund-22%
- AlumisALMS3.5% of the fund-27%
- CytokineticsCYTK3.2% of the fund-42%
- Enliven TherapeuticsELVN3.1% of the fund-54%
- Vera TherapeuticsVERA2.6% of the fund-15%
- UnitedHealth GroupUNH2.5% of the fund-25%
- 10x GenomicsTXG2.4% of the fund-33%
- NateraNTRA2.3% of the fund-26%
- Rhythm PharmaceuticalsRYTM2.2% of the fund-21%
- Monte Rosa TherapeuticsGLUE2.0% of the fund-24%
- MoonLake ImmunotherapeuticsMLTX2.0% of the fund-23%
- Alkermes plc.ALKS2.0% of the fund-27%
- LiquidiaLQDA1.9% of the fund-14%
- United TherapeuticsUTHR1.8% of the fund-23%
- GlaukosGKOS1.7% of the fund-5%
- Arrowhead PharmaceuticalsARWR1.6% of the fund-30%
- Agios PharmaceuticalsAGIO1.6% of the fund-44%
- Crescent BiopharmaCBIO1.4% of the fund-17%
- AdageneADAG1.3% of the fund-34%
- Intuitive SurgicalISRG1.2% of the fund-23%
- Corbus Pharmaceuticals HoldingsCRBP1.1% of the fund-21%
Sold out
Sold their entire stake.
- Elevance HealthELV-100%
- Apellis Pharmaceuticals-100%
- Avalo TherapeuticsAVTX-100%
- Soleno Therapeutics-100%
- 4D Molecular TherapeuticsFDMT-100%
- NextCureNXTC-100%
- Palisade BIOPALI-100%
- LipocineLPCN-100%
Holdings
- Abivax SAABVX
- Share
- 3.9%
- Value
- $6m
- Shares
- 46,878
New
- Novabridge BiosciencesNBP
- Share
- 0.7%
- Value
- $1m
- Shares
- 576,960
Held
- Bright Minds BiosciencesDRUG
- Share
- 0.4%
- Value
- $709,722
- Shares
- 10,110
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Guardant HealthGH | 6.2% | $10m | 67,500 | -18% |
| Praxis Precision MedicinesPRAX | 5.6% | $9m | 27,205 | -40% |
| TG TherapeuticsTGTX | 5.6% | $9m | 164,915 | New |
| Cogent BiosciencesCOGT | 5.0% | $8m | 210,523 | -24% |
| Ionis PharmaceuticalsIONS | 4.3% | $7m | 88,177 | -20% |
| Eli LillyLLY | 4.1% | $7m | 5,492 | -22% |
| Abivax SAABVX | 3.9% | $6m | 46,878 | New |
| AlumisALMS | 3.5% | $6m | 204,418 | -27% |
| CytokineticsCYTK | 3.2% | $5m | 60,056 | -42% |
| Enliven TherapeuticsELVN | 3.1% | $5m | 100,203 | -54% |
| Vera TherapeuticsVERA | 2.6% | $4m | 97,276 | -15% |
| UnitedHealth GroupUNH | 2.5% | $4m | 9,612 | -25% |
| 10x GenomicsTXG | 2.4% | $4m | 102,629 | -33% |
| NateraNTRA | 2.3% | $4m | 13,800 | -26% |
| uniQureQURE | 2.3% | $4m | 81,056 | New |
| Rhythm PharmaceuticalsRYTM | 2.2% | $4m | 32,209 | -21% |
| Maze TherapeuticsMAZE | 2.1% | $3m | 114,692 | +30% |
| Monte Rosa TherapeuticsGLUE | 2.0% | $3m | 137,115 | -24% |
| MoonLake ImmunotherapeuticsMLTX | 2.0% | $3m | 166,493 | -23% |
| Alkermes plc.ALKS | 2.0% | $3m | 61,336 | -27% |
| LiquidiaLQDA | 1.9% | $3m | 39,224 | -14% |
| United TherapeuticsUTHR | 1.8% | $3m | 5,410 | -23% |
| GlaukosGKOS | 1.7% | $3m | 19,862 | -5% |
| Arrowhead PharmaceuticalsARWR | 1.6% | $3m | 32,214 | -30% |
| Agios PharmaceuticalsAGIO | 1.6% | $3m | 70,500 | -44% |
| Crescent BiopharmaCBIO | 1.4% | $2m | 127,769 | -17% |
| AstrazenecaAZN | 1.4% | $2m | 12,045 | New |
| Boston ScientificBSX | 1.3% | $2m | 48,347 | Held |
| AdageneADAG | 1.3% | $2m | 488,293 | -34% |
| PenumbraPEN | 1.2% | $2m | 6,300 | Held |
| Intuitive SurgicalISRG | 1.2% | $2m | 4,908 | -23% |
| Viking TherapeuticsVKTX | 1.2% | $2m | 47,861 | New |
| Ocular TherapeutixOCUL | 1.1% | $2m | 181,588 | New |
| EquilliumEQ | 1.1% | $2m | 552,956 | New |
| Ascendis Pharma A/SASND | 1.1% | $2m | 6,573 | New |
| Corbus Pharmaceuticals HoldingsCRBP | 1.1% | $2m | 184,914 | -21% |
| CytomX TherapeuticsCTMX | 1.1% | $2m | 460,067 | -12% |
| VerastemVSTM | 1.0% | $2m | 429,041 | -33% |
| Nektar TherapeuticsNKTR | 1.0% | $2m | 22,417 | New |
| ClearPoint NeuroCLPT | 0.9% | $1m | 83,636 | New |
| InsmedINSM | 0.9% | $1m | 13,873 | -48% |
| Caris Life SciencesCAI | 0.9% | $1m | 78,180 | New |
| BridgeBio PharmaBBIO | 0.8% | $1m | 18,359 | -73% |
| Zenas BioPharmaZBIO | 0.8% | $1m | 52,443 | -35% |
| Novabridge BiosciencesNBP | 0.7% | $1m | 576,960 | Held |
| Establishment Labs HoldingsESTA | 0.7% | $1m | 13,100 | Held |
| Relay TherapeuticsRLAY | 0.5% | $889,305 | 47,531 | -83% |
| GeronGERN | 0.5% | $798,779 | 624,046 | New |
| Bright Minds BiosciencesDRUG | 0.4% | $709,722 | 10,110 | New |
| Compass TherapeuticsCMPX | 0.4% | $604,801 | 276,165 | New |
| Replimune GroupREPL | 0.3% | $446,796 | 40,361 | New |
| Arbutus BiopharmaABUS | 0.1% | $240,797 | 50,166 | -34% |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 33.7% since 30 June 2025.
Where the money is
Health care95.5%
Other4.5%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.